Objective
Bacterial pathogens possess the ability to adapt rapidly to changing environmental conditions which is especially apparent in the hospital setting where bacteria acquire antibiotic resistances readily. Besides well studied mechanisms such as horizontal gene transfer bacteria can alter the genetic material by acquiring gen duplications and amplifications (GDA). Exemplarily an improved gene dosage of a minor resistance determinant can lead to increased resistance to antibiotics. Due to the difficulties in their detection GDAs are almost exclusively studied in model organisms and neglected in natural populations of clinically relevant species such as Staphylococcus aureus. Accordingly many important questions about the frequency and clinical importance of GDAs remain unanswered. State of the art sequencing technologies enable the identification of GDAs by analysis of the coverage scaffold and groundbreaking experiments using 387 USA300 genome sequences showed promising results regarding putative copy number variation of virulence factors. We will extend the GDA analysis to ca. 1200 already available EMRSA15 sequences. This will enable a comprising analysis of gen copy number variation in clinical isolates and might allow identifying genomic regions under strong evolutionary pressure during infection. We will optimize experimental setups for the rapid validation of GDAs by qPCR and develop techniques to study the effects of GDAs in S. aureus. Furthermore we will sequence a selection ca. 70 S. aureus isolates causing chronic infections in patients suffering from cystic fibrosis (CF). This will enable us to optimize the detection of GDAs by NGS and will allow investigating the role of GDAs during adaption to the complex environment within the CF-lung. This project will show new avenues to extract additional valuable biological information from NGS data and will investigate the importance of GDAs during the adaption of S. aureus to the hospital setting and to the CF-lung.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences medical biotechnology genetic engineering gene therapy
- medical and health sciences basic medicine immunology
- medical and health sciences clinical medicine pneumology tuberculosis
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs antibiotics
- medical and health sciences basic medicine pharmacology and pharmacy drug resistance antibiotic resistance
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
MSCA-IF-EF-ST - Standard EF
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-MSCA-IF-2014
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
72074 Tuebingen
Germany
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.